Novo Nordisk A/S (BKK:NOVOB80)

Market Cap	6.85T -43.9%
Revenue (ttm)	1.53T +6.4%
Net Income	507.86B +1.4%
EPS	114.18 +1.8%
Shares Out	n/a
PE Ratio	13.48
Forward PE	14.75
Dividend	0.04 (2.62%)
Ex-Dividend Date	Aug 15, 2025

Volume	11,048,840
Average Volume	12,501,058
Open	1.480
Previous Close	1.470
Day's Range	1.460 - 1.590
52-Week Range	1.370 - 3.240
Beta	n/a
RSI	38.97
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers pro...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 78,554
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: NOVOB80

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK